ZA200300406B - Somatostatin analogues. - Google Patents

Somatostatin analogues.

Info

Publication number
ZA200300406B
ZA200300406B ZA200300406A ZA200300406A ZA200300406B ZA 200300406 B ZA200300406 B ZA 200300406B ZA 200300406 A ZA200300406 A ZA 200300406A ZA 200300406 A ZA200300406 A ZA 200300406A ZA 200300406 B ZA200300406 B ZA 200300406B
Authority
ZA
South Africa
Prior art keywords
somatostatin analogues
somatostatin
analogues
Prior art date
Application number
ZA200300406A
Other languages
English (en)
Inventor
Rainer Albert
David Bodmer
Ivo Felner
Ian Lewis
Gisbert Weckbecker
Wilfried Bauer
Christian Bruns
Heribert Hellstern
Mark Meisenbach
Bernhard Wietfeld
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9896782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200300406(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200300406B publication Critical patent/ZA200300406B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
ZA200300406A 2000-08-01 2003-01-15 Somatostatin analogues. ZA200300406B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0018891.2A GB0018891D0 (en) 2000-08-01 2000-08-01 Organic compounds

Publications (1)

Publication Number Publication Date
ZA200300406B true ZA200300406B (en) 2004-04-02

Family

ID=9896782

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200300406A ZA200300406B (en) 2000-08-01 2003-01-15 Somatostatin analogues.

Country Status (36)

Country Link
US (5) US7473761B2 (de)
EP (1) EP1307486B1 (de)
JP (1) JP3829118B2 (de)
KR (2) KR100799394B1 (de)
CN (1) CN1267451C (de)
AR (1) AR034132A1 (de)
AT (1) ATE393782T1 (de)
AU (2) AU8977801A (de)
BE (1) BE2012C026I2 (de)
BR (1) BRPI0112859B8 (de)
CA (1) CA2416293C (de)
CY (2) CY1108547T1 (de)
CZ (1) CZ302461B6 (de)
DE (1) DE60133823T2 (de)
DK (1) DK1307486T3 (de)
EC (1) ECSP034456A (de)
ES (1) ES2305104T3 (de)
FR (1) FR12C0041I2 (de)
GB (1) GB0018891D0 (de)
HK (1) HK1057051A1 (de)
HU (1) HU227812B1 (de)
IL (2) IL153920A0 (de)
LU (1) LU92024I2 (de)
MX (1) MXPA03000991A (de)
MY (1) MY138074A (de)
NO (2) NO331093B1 (de)
NZ (1) NZ523836A (de)
PE (1) PE20020176A1 (de)
PL (1) PL204161B1 (de)
PT (1) PT1307486E (de)
RU (1) RU2287533C2 (de)
SI (1) SI1307486T1 (de)
SK (1) SK287798B6 (de)
TW (1) TWI282341B (de)
WO (1) WO2002010192A2 (de)
ZA (1) ZA200300406B (de)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
AU2002359359A1 (en) 2001-12-28 2003-07-24 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
BR0317176A (pt) * 2002-12-12 2005-10-25 Novartis Ag Processo para a sìntese de peptìdeos contendo uma subestrutura de 4-hidróxi-prolina
GB0229020D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic compounds
GB0300095D0 (en) * 2003-01-03 2003-02-05 Novartis Ag Organic compounds
PE20050285A1 (es) * 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
GB0314695D0 (en) * 2003-06-24 2003-07-30 Novartis Ag Organic compounds
GB0318682D0 (en) * 2003-08-08 2003-09-10 Novartis Ag Organic compounds
EP1522311A1 (de) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von Somatostatin oder seine Derivate zur Herstellung eines Medikamentes zur Regulierung der Ovarialfollikelnreserve bei der nicht menopausierte Frau
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
GB0412866D0 (en) * 2004-06-09 2004-07-14 Novartis Ag Organic compounds
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
AU2007255416A1 (en) * 2006-06-08 2007-12-13 Novartis Ag Combination of somatostatin-analogs with dopamine- or growth hormone receptor antagonist
US7697338B2 (en) * 2006-11-16 2010-04-13 Sandisk Corporation Systems for controlled boosting in non-volatile memory soft programming
WO2008064570A1 (en) * 2006-11-28 2008-06-05 The University Of Hong Kong The use of granulin-epithelin precursor (gep) antibodies for detection and suppression of hepatocellular carcinoma (hcc)
EP1941902A1 (de) * 2007-01-02 2008-07-09 Novartis AG Verwendung von Somatostatin Analogen zur Behandlung von Cluster Kopfschmerzen
WO2008095063A1 (en) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
PE20090387A1 (es) 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
WO2009009035A1 (en) * 2007-07-06 2009-01-15 Ipsen Pharma S.A.S. Somatostatin analog and uses thereof
GB0719818D0 (en) * 2007-10-11 2007-11-21 Asterion Ltd Growth hormone fusion polypeptides
ES2536778T3 (es) * 2007-11-28 2015-05-28 Novartis Ag Uso de análogos de somatostatina en meningioma
SI2225271T1 (sl) 2007-12-03 2013-10-30 Italfarmaco S.P.A. Novi selektivni analogi somatostatina
EP2067786A1 (de) 2007-12-07 2009-06-10 ITALFARMACO S.p.A. Neue nichtselektive Analoga von Somatostatin
US20090325863A1 (en) * 2008-06-13 2009-12-31 Kleinberg David L Somatostatin analogs and IGF-I inhibition for breast cancer prevention
PT2310042E (pt) 2008-07-08 2013-03-11 Novartis Ag Uso de pasireotido para o tratamento de hipoglicemia hiperinsulinémica endógena
EP2213307A1 (de) 2009-02-03 2010-08-04 Novartis AG Injizierbare Depotformulierungen
EP2172189A1 (de) 2008-10-01 2010-04-07 Novartis AG Pharmazeutische Zusammensetzungen
RU2552324C2 (ru) 2008-09-17 2015-06-10 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
US8629103B2 (en) 2010-12-02 2014-01-14 New York University Treatment of non-proliferative cystic disease of the breast
WO2012080260A1 (en) 2010-12-13 2012-06-21 Novartis Ag Dimeric iap inhibitors
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
US20130035054A1 (en) * 2011-07-14 2013-02-07 Faceon Mobile Phone with multi-portal access for display during incoming and outgoing call
WO2013019923A2 (en) 2011-08-02 2013-02-07 New York University Methods for detecting progenitor cells and uses thereof
GEP20166432B (en) 2011-09-27 2016-02-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
CA2856824A1 (en) 2011-12-05 2013-06-13 Novartis Ag Cyclic urea derivatives as androgen receptor antagonists
DK2787974T3 (en) 2011-12-05 2017-07-17 Camurus Ab Robust PEPTID FORMULATIONS WITH CONTROLLED RELEASE
US10023862B2 (en) 2012-01-09 2018-07-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat beta-catenin-related diseases
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
NZ702028A (en) * 2012-05-25 2016-07-29 Camurus Ab Somatostatin receptor agonist formulations
TWI704919B (zh) 2012-05-31 2020-09-21 日商大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
US9480759B2 (en) 2012-11-21 2016-11-01 Serene, Llc Tin-117m somatostatin receptor binding compounds and methods
AU2014219283C1 (en) 2013-02-19 2016-10-27 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
AU2014229283B2 (en) 2013-03-14 2016-07-28 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
WO2014147586A1 (en) 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
CN103467575B (zh) * 2013-08-22 2016-03-02 深圳翰宇药业股份有限公司 一种帕西瑞肽的制备方法
CN103641894B (zh) * 2013-12-06 2015-10-28 深圳翰宇药业股份有限公司 一种治疗库欣病的多肽药物的制备方法
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
CA2929117A1 (en) 2013-12-19 2015-06-25 Novartis Ag Drug delivery systems
WO2015107493A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3094629B1 (de) 2014-01-17 2018-08-22 Novartis AG 1-(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idin-derivate und zusammensetzungen davon zur hemmung der aktivität von shp2
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
BR122024001145A2 (pt) 2014-03-14 2024-02-27 Novartis Ag Molécula de anticorpo isolada capaz de se ligar a lag-3, seu método de produção, composição farmacêutica, ácidos nucleicos, vetor de expressão, método para detecção de lag-3 em uma amostra biológica, e uso das referidas molécula de anticorpo e composição
KR20170005492A (ko) 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
EP3226689B1 (de) 2014-12-05 2020-01-15 Merck Sharp & Dohme Corp. Neuartige tricyclische verbindungen als inhibitoren von mutanten idh-enzymen
WO2016089833A1 (en) 2014-12-05 2016-06-09 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
US10442819B2 (en) 2014-12-05 2019-10-15 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
US20160193285A1 (en) 2014-12-10 2016-07-07 Chiasma Inc. Oral octreotide administered in combination with other therapeutic agents
WO2016097962A1 (en) 2014-12-19 2016-06-23 Auro Peptides Ltd A process for the preparation of pasireotide
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
MX2017011597A (es) 2015-03-10 2018-05-11 Aduro Biotech Inc Composiciones y metodos para activar la señalizacion dependiente del "estimulador del gen de interferon".
CN107614003A (zh) 2015-03-20 2018-01-19 艾瑞朗医疗公司 拟肽大环化合物及其用途
US10730911B2 (en) 2015-04-08 2020-08-04 Universitat Zurich Backbone-cyclized peptidomimetics with GLP-1R modulating activity
WO2016189055A1 (en) 2015-05-27 2016-12-01 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer
US10308660B2 (en) 2015-06-19 2019-06-04 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
JP6718889B2 (ja) 2015-06-19 2020-07-08 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物および組成物
US10975080B2 (en) 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10556924B2 (en) 2015-06-22 2020-02-11 Biophore India Pharmaceuticals Pvt. Ltd. Process for the preparation of pasireotide
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3317301B1 (de) 2015-07-29 2021-04-07 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen lag-3
EP3316902A1 (de) 2015-07-29 2018-05-09 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen tim-3
UA123701C2 (uk) 2015-08-13 2021-05-19 Мерк Шарп І Доум Корп. Циклічні динуклеотидні сполуки як агоністи sting
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
WO2017079112A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
US10538497B2 (en) 2015-12-15 2020-01-21 Merck Sharp & Dohme Corp. Compounds as indoleamine 2,3-dioxygenase inhibitors
US20180371093A1 (en) 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
US10577362B2 (en) 2016-05-04 2020-03-03 Genoscience Pharma Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP3507367A4 (de) 2016-07-05 2020-03-25 Aduro BioTech, Inc. Cyclisches dinukleotidverbindungen mit eingeschlossenen nukleinsäuren und verwendungen davon
HUE056502T2 (hu) 2016-10-04 2022-02-28 Merck Sharp & Dohme Benzo[b]tiofén vegyületek mint STING agonisták
WO2018091542A1 (en) 2016-11-21 2018-05-24 Idenix Pharmaceuticals Llc Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
JP7275031B2 (ja) 2017-01-27 2023-05-17 ヤンセン バイオテツク，インコーポレーテツド Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド
US11021511B2 (en) 2017-01-27 2021-06-01 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3642240A1 (de) 2017-06-22 2020-04-29 Novartis AG Antikörpermoleküle gegen cd73 und verwendungen davon
CA3071537A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and benzo[b]thiophene sting agonists for cancer treatment
CA3071538A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Benzo[b]thiophene sting agonists for cancer treatment
CA3074304A1 (en) 2017-09-11 2019-03-14 Krouzon Pharmaceuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
WO2019067332A1 (en) 2017-09-27 2019-04-04 Merck Sharp & Dohme Corp. COMPOSITIONS AND METHODS FOR TREATING CANCER THROUGH A COMBINATION OF PROGRAMMED DEATH ANTIBODY ANTIBODIES (PD-1) AND A CXCR2 ANTAGONIST
WO2019078968A2 (en) * 2017-10-18 2019-04-25 Angex Pharmaceutical, Inc. CYCLIC COMPOUNDS AS IMMUNOMODULATORS
US20210179607A1 (en) 2017-11-01 2021-06-17 Merck Sharp & Dohme Corp. Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
WO2019099294A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CA3082108A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
MX2020006290A (es) 2017-12-15 2020-12-03 Janssen Biotech Inc Dinucleotidos ciclicos como agonistas de sting.
WO2019125974A1 (en) 2017-12-20 2019-06-27 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
MX2020010407A (es) 2018-04-03 2020-10-22 Merck Sharp & Dohme Benzotiofenos y compuestos relacionados como agonistas de sting.
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3810116B1 (de) 2018-05-31 2023-11-15 Merck Sharp & Dohme LLC Neuartige substituierte [1.1.1]-bicyclo-verbindungen als indolamin-2,3-dioxygenase-inhibitoren
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
JP7542538B2 (ja) 2018-09-18 2024-08-30 ニカング セラピューティクス， インコーポレイテッド Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体
CA3113241A1 (en) 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
JP2022502496A (ja) 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤組成物、作製方法、および使用方法
EP3856345A1 (de) 2018-09-29 2021-08-04 Novartis AG Verfahren zur herstellung einer verbindung zur hemmung der aktivität von shp2
EP3873464A4 (de) 2018-11-01 2022-06-08 Merck Sharp & Dohme Corp. Neuartige substituierte pyrazolverbindungen als indolamin-2,3-dioxygenase-inhibitoren
EP3877366A4 (de) 2018-11-06 2022-08-24 Merck Sharp & Dohme Corp. Neuartige substituierte tricyclische verbindungen als indolamin-2,3-dioxygenase-inhibitoren
EP3886845B1 (de) 2018-11-28 2024-09-04 Merck Sharp & Dohme LLC Neuartige substituierte piperazinamidverbindungen als indolamin-2, 3-dioxygenase (ido)-inhibitoren
WO2020205688A1 (en) 2019-04-04 2020-10-08 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
EP3990635A1 (de) 2019-06-27 2022-05-04 Rigontec GmbH Entwurfsverfahren für optimierte rig-i-liganden
MX2022001407A (es) 2019-08-02 2022-04-27 Mersana Therapeutics Inc Compuestos derivados y relacionados de bis-[n-((5-carbamoil)-1h be nzo[d]imidazol-2-yl)-pyrazol-5-carboxamida] como agonistas de sting (estimulador de genes de interferón) para el tratamiento de cáncer.
CA3150701A1 (en) 2019-08-15 2021-02-18 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
EP4031578A1 (de) 2019-09-18 2022-07-27 Novartis AG Entpd2-antikörper, kombinationstherapien und verfahren zur verwendung der antikörper und kombinationstherapien
CN114829357A (zh) 2019-10-28 2022-07-29 中国科学院上海药物研究所 五元杂环氧代羧酸类化合物及其医药用途
WO2021113679A1 (en) 2019-12-06 2021-06-10 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
WO2021195206A1 (en) 2020-03-24 2021-09-30 Black Diamond Therapeutics, Inc. Polymorphic forms and related uses
CA3177442A1 (en) 2020-05-06 2021-11-11 Brandon D. Cash Il4i1 inhibitors and methods of use
EP4267575A1 (de) 2020-12-22 2023-11-01 Nikang Therapeutics, Inc. Verbindungen zum abbau von cyclin-abhängiger kinase 2 über den ubiquitinproteosomenweg
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CA3208313A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2022170052A1 (en) 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
EP4323350A1 (de) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Isoindolinonverbindungen
WO2022219412A1 (en) 2021-04-14 2022-10-20 Monte Rosa Therapeutics Ag Isoindolinone amide compounds useful to treat diseases associated with gspt1
WO2022227015A1 (en) 2021-04-30 2022-11-03 Merck Sharp & Dohme Corp. Il4i1 inhibitors and methods of use
EP4370522A1 (de) 2021-07-14 2024-05-22 Nikang Therapeutics, Inc. Alkylidenderivate als kras-hemmer
TW202346292A (zh) 2022-03-28 2023-12-01 美商尼坎醫療公司 作為週期蛋白依賴性激酶２抑制劑的磺醯胺基衍生物
WO2023240024A1 (en) 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2024047112A1 (en) * 2022-08-30 2024-03-07 Somtheranostics Sarl Halogenated somatostatin analogs with multiple somatostatin receptor subtype selectivity
WO2024102849A1 (en) 2022-11-11 2024-05-16 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2024206357A1 (en) 2023-03-29 2024-10-03 Merck Sharp & Dohme Llc Il4i1 inhibitors and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3863008A (en) 1973-06-11 1975-01-28 American Home Prod Somatostatin as stimulant of luteinizing hormone secretion
NZ195303A (en) 1979-10-31 1984-10-19 Merck & Co Inc Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions
US4292972A (en) 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4612386A (en) * 1980-09-16 1986-09-16 The Dow Chemical Company Process for making esters
US4505897A (en) 1983-04-18 1985-03-19 The Administrators Of The Tulane Educational Fund Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
US4612366A (en) 1985-06-17 1986-09-16 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
CA2012115C (en) 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
CA2053250A1 (en) 1989-04-26 1990-10-27 David H. Coy Linear somatostatin analogs
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
DE69434832D1 (de) 1993-06-23 2006-10-05 Diatide Inc Radioaktiv-markierte Peptidderivate des Somatostatins zur bildformenden und therapeutischen Verwendung
UA44707C2 (uk) 1993-08-09 2002-03-15 Біомежер, Інк. Похідні пептидів та спосіб лікування раку
US5770687A (en) 1995-06-07 1998-06-23 Peptor Limited Comformationally constrained backbone cyclized somatostatin analogs
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
IT1277391B1 (it) 1995-07-28 1997-11-10 Romano Deghenghi Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
AU2764797A (en) 1996-05-14 1997-12-05 Novo Nordisk A/S Somatostatin agonists and antagonists
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
CA2246791A1 (en) 1998-09-01 2000-03-01 Alison Buchan Treatment of endothelium with somatostatin analogues
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ATE393782T1 (de) 2008-05-15
ES2305104T3 (es) 2008-11-01
SK1212003A3 (en) 2003-08-05
MXPA03000991A (es) 2003-06-09
HU227812B1 (hu) 2012-03-28
US7939625B2 (en) 2011-05-10
LU92024I2 (fr) 2012-08-20
CA2416293C (en) 2011-05-10
DE60133823D1 (de) 2008-06-12
US20150218223A1 (en) 2015-08-06
CZ2003288A3 (cs) 2003-05-14
NO20030484L (no) 2003-03-19
CZ302461B6 (cs) 2011-06-01
AU8977801A (en) 2002-02-13
DK1307486T3 (da) 2008-08-25
CA2416293A1 (en) 2002-02-07
GB0018891D0 (en) 2000-09-20
US20110172157A1 (en) 2011-07-14
NO2012012I2 (no) 2012-07-30
CN1267451C (zh) 2006-08-02
MY138074A (en) 2009-04-30
WO2002010192A9 (en) 2002-10-17
PL358718A1 (en) 2004-08-09
EP1307486A2 (de) 2003-05-07
PE20020176A1 (es) 2002-03-26
KR100799394B1 (ko) 2008-01-30
IL153920A (en) 2010-12-30
US8822637B2 (en) 2014-09-02
CY2012018I2 (el) 2015-10-07
ECSP034456A (es) 2003-03-10
EP1307486B1 (de) 2008-04-30
US9035021B2 (en) 2015-05-19
JP2004505095A (ja) 2004-02-19
NO331093B1 (no) 2011-10-03
CY1108547T1 (el) 2014-04-09
RU2287533C2 (ru) 2006-11-20
JP3829118B2 (ja) 2006-10-04
NO2012012I1 (no) 2012-06-29
SK287798B6 (sk) 2011-10-04
US7473761B2 (en) 2009-01-06
WO2002010192A2 (en) 2002-02-07
US20050014686A1 (en) 2005-01-20
NO20030484D0 (no) 2003-01-30
US20110166320A1 (en) 2011-07-07
HK1057051A1 (en) 2004-03-12
BRPI0112859B8 (pt) 2021-05-25
TWI282341B (en) 2007-06-11
FR12C0041I1 (de) 2012-07-27
US20090069225A1 (en) 2009-03-12
BR0112859A (pt) 2003-07-01
BRPI0112859B1 (pt) 2016-03-01
IL153920A0 (en) 2003-07-31
KR20060035809A (ko) 2006-04-26
FR12C0041I2 (fr) 2013-01-11
KR20030033008A (ko) 2003-04-26
CN1446229A (zh) 2003-10-01
CY2012018I1 (el) 2015-10-07
HUP0300684A2 (hu) 2003-09-29
PT1307486E (pt) 2008-07-31
BE2012C026I2 (de) 2020-12-15
PL204161B1 (pl) 2009-12-31
HUP0300684A3 (en) 2004-08-30
DE60133823T2 (de) 2009-05-20
NZ523836A (en) 2004-08-27
AU2001289778B2 (en) 2005-02-03
SI1307486T1 (sl) 2008-08-31
AR034132A1 (es) 2004-02-04
WO2002010192A3 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
ZA200300406B (en) Somatostatin analogues.
MXPA03002410A (es) 4-amino-quinazolinas.
ZA200205479B (en) Novel biarylcarboxamides.
GB0128526D0 (en) Nucleotide analogues
EG23262A (en) Delta -pyrrolines.
HK1056872A1 (en) Indoloquinazolinones.
MXPA03001591A (es) Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal.
MXPA03009048A (es) Agonistas de la somatostatina.
ZA200203390B (en) Vitamin D analogues.
MXPA03001877A (es) 2-guanidin-4-arilquinazolinas.
MXPA03002668A (es) Guanidinas de sulfonilo.
MXPA03001991A (es) Novedosas arilalcano-sulfonamidas.
MXPA03005714A (es) Sulfamidotienopirimidinas.
MXPA03002411A (es) 4-amino-quinazolinas.
ZA200106875B (en) Trace elements.
MXPA03005494A (es) Benzoilpiridazinas.
HK1061560A1 (en) Triazolo-epothilones.
GB0022877D0 (en) Analogues
GB0002612D0 (en) C.m.e
HK1051197A1 (en) Novel vitamin d analogues.
ZA200302241B (en) Triazolo-epothilones.
TJ414B (en) Thermoresistor.
GB0024269D0 (en) D.p.s.
ZA200103473B (en) Headware.
GB0027716D0 (en) P:c:d.